Radiopharmaceutical Cold Kit Production Without Lyophilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production of radiopharmaceutical cold kits, particularly those using Technetium-99m, is hindered by the costly and time-consuming lyophilization process, which also increases the risk of microbial contamination.
Innovation Solution
A method that eliminates the lyophilization step by maintaining all ingredients in a dry powdered form throughout the production process, involving trituration of active ingredients with bulk inactive ingredients in an inert atmosphere, sterilization, and filling sterile vials with an inert gas.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lyophilization is used in the production process, then the radiopharmaceutical cold kits achieve stable and sterile quality, but the production cost increases and production time is extended
Solution Approach 1:
The patent extracts and eliminates the lyophilization step from the production process. By removing this complex freezing and drying operation, the process achieves both cost reduction and time savings while maintaining product quality through alternative sterile processing methods
Solution Approach 2:
The patent changes the physical state parameter of the ingredients from requiring frozen-dried solid form to using sterile powdered form. This parameter change eliminates the need for lyophilization while maintaining sterility and stability through proper powder handling and inert atmosphere techniques
2Reliability
If lyophilization is used in the production process, then the radiopharmaceutical cold kits achieve stable and sterile quality, but the production cost increases
Solution Approach 1:
The patent extracts and eliminates the lyophilization step from the production process. By removing this complex freezing and drying operation, the process achieves both cost reduction and time savings while maintaining product quality through alternative sterile processing methods
Solution Approach 2:
The patent replaces the expensive and time-consuming lyophilization equipment and process with simpler, more cost-effective sterile powder handling techniques, including filtration and inert atmosphere methods that are less capital intensive
3Ease of operation
If water is used in the kit production process, then the ingredients can be dissolved and mixed, but the risk of microbial contamination increases
Solution Approach 1:
The patent uses an inert atmosphere (nitrogen or other inert gas) throughout the production process to exclude oxygen and moisture. This prevents microbial growth while allowing proper mixing and formulation of the cold kit ingredients in a controlled environment
Solution Approach 2:
The patent extracts water from the production process by using sterile powders that are mixed and handled in an inert atmosphere, eliminating the aqueous environment that would support microbial contamination while maintaining the ability to dissolve and mix ingredients when needed
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach reduces production costs and time while minimizing contamination risks, enabling the efficient production of stable and sterile radiopharmaceutical cold kits.
Implementation Method 1
filling the vials with an inert gas
Data Source
AI summary
A method for making a radiopharmaceutical cold kit without lyophilization, comprising (1) providing a labeling ligand, a reducing agent, and a bulking agent, and at least one of an antioxidant and an exchange ligand, wherein each of said labeling ligand, reducing agent, bulking agent, antioxidant and exchange ligand is provided in a dry form; and (2) combining and mixing the labeling ligand, the reducing agent, the bulking agent, and at least one of the antioxidant and the exchange ligand to produce a dry powder mixture, wherein the wherein the dry powder mixture is produced without the use of a lyophilization step. The radiopharmaceutical cold kit comprising the dry powder mixture may be stored, or combined with a radionuclide such as Technetium-99m (99mTc).